Actively Recruiting
SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation
Led by Seoul National University Hospital · Updated on 2026-04-28
204
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, randomized controlled trial to compare the recurrence of 1-year atrial arrhythmia after catheter ablation of atrial fibrillation (AF) between pulmonary vein isolation (PVI) and PVI with additional left atrial (LA) substrate modification based on the left atrial low-voltage area (LA LVA) in patients with persistent AF who had a moderate burden of LVA in LA (1cm2 to \<30%).
CONDITIONS
Official Title
SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 19 years or older
- Symptomatic persistent atrial fibrillation continuing despite anti-arrhythmic drugs
- Left atrial low-voltage area (LVA) between 1cm2 and less than 30% on 3D voltage mapping
- Patients with LVA less than 1cm2 or 30% or more are included in a registry but not randomized
You will not qualify if you...
- Left atrial anteroposterior diameter greater than 55 mm
- Prior catheter ablation or surgery for atrial fibrillation
- Inability to obtain high-quality 3D voltage mapping or calculate exact LVA burden
- Inability or unwillingness to use anticoagulation treatment
- Severe left ventricular dysfunction (ejection fraction less than 35%)
- Severe structural heart disease including severe mitral regurgitation, hypertrophic cardiomyopathy, or other severe valve disease
- Presence of intracardiac thrombus
- Prior cardiac surgery
- Myocardial infarction or coronary intervention within 3 months
- Stroke or transient ischemic attack within 6 months
- Planned cardiovascular surgery or procedure
- Uncontrolled hypertension or thyroid disease
- Need for dialysis or scheduled dialysis
- Current pregnancy or pregnancy likely during study
- Use of immunosuppressive drugs or recent chemotherapy
- Life expectancy less than 1 year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University Hospital
Seoul, Jongno-gu, South Korea, 03080
Actively Recruiting
Research Team
E
Eue-Keun Choi, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here